CMRX - キメリックス （Chimerix Inc.）

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve’s possible response. If we’re being honest, circumstances don’t look particularly auspicious. Then again, the beauty of biotech stocks to buy is that medical innovations will continue moving forward. Poor economy or not, scientists continue to search for treatments for difficult-to-address diseases and conditions. Under this framework, you might say that the biotech sector is somewhat insulated from the ebb and flow of the economy. For this specific write-up, I’ll be discussing truly thrilling biotech stocks to buy. Each of these securities features (at the time of writing) consensus analyst price targets that imply a minimum of 100% upside potential.

Amid funding woes at SVB Financial (SIVB), biotech Chimerix (CMRX), said Friday that its exposure to liquidity concerns at the Silicon Valley Bank is "immaterial." Read the full story here.

The following slide deck was published by Chimerix, Inc.

Chimerix took quite a skid as it passed into the danger zone. Recognizing that CMRX is at the top of the risk spectrum, see why I still rate it as a strong buy.

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.

Chimerix, Inc. (NASDAQ:NASDAQ:CMRX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ETCompany ParticipantsMichelle LaSpaluto - Vice President-Strategic Planning and Investor…

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Chimerix Inc. (CMRX) on Thursday reported a loss of $21 million in…

Chimerix press release (CMRX): Q4 GAAP EPS of -$0.24 in-line.Revenue of $0.8M (+1500.0% Y/Y) beats by $0.22M.“As we look to 2023, we are making tremendous progress and continuing…

- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study –

Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.

Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.

The contract, awarded by the Public Health Agency of Canada, comes a day after Chimerix announced an order worth $9.3-million for the smallpox drug, Tembexa

The shares of Chimerix (CMRX) rose on Friday after the company announced that Public Health Agency of Canada awarded it a contract to deliver up to $25.3M of Tembexa (brincidofovir),…

Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads across the world.